HC Wainwright Reaffirms Buy Rating for Fennec Pharmaceuticals (NASDAQ:FENC)

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $13.00 price target on the stock. HC Wainwright's price target points to a potential upside of 65.18% from the company's previous close. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.14) EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.26 EPS and FY2026 earnings at $0.66 EPS.

Several other equities research analysts have also commented on the stock. Craig Hallum boosted their price objective on shares of Fennec Pharmaceuticals from $12.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Wedbush reiterated an "outperform" rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Monday, March 10th.

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock traded down $0.10 during trading on Tuesday, hitting $7.87. The company's stock had a trading volume of 66,142 shares, compared to its average volume of 96,821. The stock has a market cap of $217.36 million, a price-to-earnings ratio of -78.69 and a beta of 0.32. The stock has a 50-day moving average price of $6.06 and a two-hundred day moving average price of $6.05. Fennec Pharmaceuticals has a 52 week low of $3.96 and a 52 week high of $8.56.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $8.18 million. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%. During the same period in the prior year, the firm posted $0.41 EPS. On average, equities analysts predict that Fennec Pharmaceuticals will post -0.11 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jeffrey S. Hackman bought 13,965 shares of Fennec Pharmaceuticals stock in a transaction on Monday, May 19th. The shares were bought at an average cost of $6.99 per share, for a total transaction of $97,615.35. Following the acquisition, the chief executive officer now owns 15,000 shares in the company, valued at approximately $104,850. This trade represents a 1,349.28% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Rosty Raykov sold 10,000 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total transaction of $67,900.00. Following the transaction, the director now directly owns 68,725 shares of the company's stock, valued at approximately $466,642.75. This represents a 12.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,000 shares of company stock worth $183,500 over the last 90 days. 11.76% of the stock is owned by insiders.

Institutional Trading of Fennec Pharmaceuticals

Several large investors have recently bought and sold shares of FENC. AQR Capital Management LLC purchased a new position in shares of Fennec Pharmaceuticals during the 1st quarter valued at approximately $66,000. Intech Investment Management LLC bought a new position in Fennec Pharmaceuticals during the fourth quarter worth $69,000. Wells Fargo & Company MN lifted its stake in Fennec Pharmaceuticals by 31.6% during the fourth quarter. Wells Fargo & Company MN now owns 13,152 shares of the company's stock worth $83,000 after purchasing an additional 3,155 shares during the last quarter. Jane Street Group LLC bought a new position in Fennec Pharmaceuticals during the first quarter worth $90,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in Fennec Pharmaceuticals during the fourth quarter worth $97,000. Institutional investors and hedge funds own 55.51% of the company's stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.